{
    "Trade/Device Name(s)": [
        "EliA CENP Immunoassay",
        "EliA U1RNP Immunoassay",
        "EliA RNP70 Immunoassay"
    ],
    "Submitter Information": "Phadia AB",
    "510(k) Number": "K182353",
    "Predicate Device Reference 510(k) Number(s)": [
        "K082759",
        "K083117"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LJM",
        "LKO"
    ],
    "Summary Letter Date": "August 28, 2018",
    "Summary Letter Received Date": "August 29, 2018",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR866.5100"
    ],
    "Regulation Name(s)": [
        "Antinuclear antibody immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology",
        "autoimmune"
    ],
    "Analyte(s)": [
        "CENP antibodies",
        "U1RNP antibodies",
        "RNP70 antibodies"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (Li-heparin, EDTA)"
    ],
    "Specimen Container(s)": [
        "Li-heparin tube",
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Phadia 2500",
        "Phadia 5000"
    ],
    "Method(s)/Technology(ies)": [
        "Semi-quantitative immunoassay",
        "Enzyme immunoassay (EIA)",
        "Immunofluorescence measurement"
    ],
    "Methodologies": [
        "Antibody detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for EliA CENP, U1RNP, and RNP70 immunoassays for detection of antinuclear antibodies on Phadia 2500/5000 instruments",
    "Indications for Use Summary": "In vitro semi-quantitative measurement of IgG antibodies to CENP, U1RNP, or RNP70 in human serum and plasma (Li-heparin, EDTA) as aids in the clinical diagnosis of scleroderma (CREST syndrome), mixed connective tissue disease (MCTD), and systemic lupus erythematosus (SLE), used in conjunction with other laboratory and clinical findings",
    "fda_folder": "Immunology"
}